Innovating Women’s Reproductive Health Therapeutics

At ObsEva, our passion and expertise in reproductive health and pregnancy therapeutics is helping millions of women worldwide lead healthier and more fulfilling lives.

Learn more Latest Company Investor presentation

Clinical Studies

We are currently conducting six international clinical research studies.

Read more

Our Pipeline

Nolasiban

(OBE001)
Oral oxytocin
receptor antagonist

Commercial rights

  • Exclusive Worldwide (ex China)
  • Partnership with Yuyuan BioScience Technology (PRC)
Learn more

Linzagolix

(OBE2109)
Oral GnRH
receptor antagonist

Milestones

Uterine Fibroids

  • Positive 24W primary endpoint results
  • 24W primary endpoint data Q2:20
  • MAA/NDA: Q4:20 / Q1:21

Endometriosis

  • Initiated Phase 3 in Q2:19
  • Positive Phase 2b results in 2018/19

Commercial rights

  • Exclusive Worldwide (ex-Asia)
Learn more

OBE022

Oral and selective
prostaglandin F2
alpha receptor antagonist

Milestones

  • EU Phase 2a PROLONG Interim update in 60 patients Q1:20

Commercial rights

  • Exclusive Worldwide
Learn more

ObsEva to Outline Corporate Plans For 2020 and Beyond at JP Morgan Healthcare Conference in San Francisco

January 15, 2020

Phase 3 linzagolix trials expected to generate additional data in uterine fibroids in Q2:20 with first linzagolix regulatory filing planned…

Learn more

ObsEva in the media

Learn more

Other ObsEva press releases

Learn more
 

Work With Us

Are you ready to join an innovative biopharmaceutical company that’s advancing women’s reproductive health and pregnancy therapeutics? Currently we have no open vacancies but you can always join our talent community below.

Talent Community

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue